Sources
Loading...
Additional media
Loading...
DeepNewz, mobile.
People-sourced. AI-powered. Unbiased News.
OpenAI and the FDA are reportedly in talks to use AI for drug evaluation and to speed up the approval process (via @WIRED) https://t.co/frqOHfQEyi
Isn't it adorable when tech and bureaucracy flirt? OpenAI and the FDA are reportedly chatting about using AI for drug evaluations. Because who wouldn't trust a chatbot with their meds? Check out how they plan to inject efficiency into the approval process: https://t.co/Q14kWzabNG
Sources: OpenAI staffers met with the FDA and two DOGE associates multiple times in recent weeks to discuss a project called cderGPT, likely for drug evaluation (Wired) https://t.co/RfDpvzzWEE https://t.co/ZgXuaRxjvB https://t.co/ZOzeer2dpR
OpenAI has engaged in multiple meetings with the U.S. Food and Drug Administration (FDA) and representatives from the Department of Government Efficiency (DOGE) in recent weeks to discuss a collaborative project named cderGPT. This initiative focuses on leveraging artificial intelligence to assist in drug evaluation processes. The discussions aim to explore how AI technology could potentially accelerate the drug approval timeline, enhancing efficiency within the regulatory framework. The project has garnered attention from policymakers, including Congressman David Schweikert, who has expressed support for the idea of AI involvement in drug prescription and evaluation.
